U.S. Stock News

Rogers (ROG) just posted first quarter results that met revenue expectations and beat non GAAP earnings estimates, then followed up with second quarter sales guidance that pointed to higher demand and supported a positive market reaction. See our latest analysis for Rogers. The recent results sit against a strong rebound in the stock, with a 30.98% 1 month share price return and a 50.24% year to date share price return, while the 1 year total shareholder return of 119.61% contrasts with...

If you are wondering whether Thermo Fisher Scientific at around US$472.95 is genuinely good value or just pricing in high expectations, the starting point is to look closely at what the current valuation is really saying. The stock has returned 1.4% over the last 7 days, a 3.1% decline over the last 30 days, a 20.2% decline year to date, but a 16.4% gain over the last year, which gives a mixed picture of sentiment and risk appetite over different time frames. Recent headlines have focused on...

Gartner (IT) has put fresh numbers on the board for Q1 2026, reporting revenue of US$1.5b and basic EPS of US$3.19 off net income of US$222.3m, setting the tone for how you might think about the rest of the year. Over recent quarters the company has seen revenue move between US$1.5b and US$1.8b, while quarterly EPS has ranged from US$0.47 to US$5.14, providing a clear view of how earnings power has fluctuated into this latest print. With trailing net margins now sitting well below last year’s...

If you are wondering whether SoFi Technologies at around US$16.30 is starting to look expensive or still offers value, it helps to step back and look at what the recent price action and fundamentals are really saying. The stock has seen mixed returns, with a 5.0% move over the last 7 days, 0.2% over 30 days, a 40.6% decline year to date, and a 25.3% return over the past year. These shifts can change how investors think about both its growth potential and risk. Recent coverage has focused on...

If you are wondering whether Edwards Lifesciences at around US$83.20 still offers value, the key question is how its current price stacks up against what the business may be worth. The stock has returned 2.4% over the past week and 2.5% over the past month, with a 10.9% return over the last year but a year to date return of 2.5% decline and softer 3 year and 5 year returns of 6.4% and 4.9% declines. Recent headlines around Edwards Lifesciences have focused on its role in the broader medical...

Rambus (RMBS) has drawn fresh attention after launching a PCIe 7.0 Switch IP with Time Division Multiplexing, aimed at addressing bandwidth, latency, and scalability needs in AI, cloud, and high performance computing systems. See our latest analysis for Rambus. The PCIe 7.0 Switch IP news lands during a sharp upswing in Rambus’s share price, with a 1 day share price return of 10.20% and a 30 day share price return of 41.01%. The 1 year total shareholder return is very large, suggesting...

Novavax, Inc. has reported past first-quarter 2026 results showing revenue of US$139.51 million, down sharply from US$666.66 million a year earlier, and a net loss of US$9.49 million compared with prior net income of US$518.65 million. The swing from earnings per share of US$3.22 to a basic loss of US$0.06 highlights how quickly Novavax’s profitability profile has shifted as its business mix changes. Next, we’ll examine how this sharp year-on-year revenue drop and move into loss-making...

If you are wondering whether NuScale Power's current share price reflects its true worth, this article will help you size up the stock using several valuation tools. The stock recently closed at US$11.87, with returns of 0.4% over 7 days, 16.9% over 30 days, a 27.2% decline year to date, a 32.8% decline over 1 year, 47.6% over 3 years and 19.8% over 5 years. This gives you a wide range of outcomes to think about. Recent coverage has focused on NuScale Power's role in nuclear energy...

Guardant Health’s Guardant360 CDx liquid biopsy has received FDA approval as a companion diagnostic for VEPPANU, a therapy for ER+/HER2- advanced breast cancer with ESR1 mutations. This is the third ESR1 companion diagnostic approval tied to Guardant360 CDx, further linking the test to targeted breast cancer treatments. The new approval broadens the clinical use of Guardant360 CDx and deepens Guardant Health’s ties with pharmaceutical partners. For investors tracking Guardant Health...

Alkermes Q1 2026 earnings: setting the stage Alkermes (ALKS) heads into Q1 2026 following its Q4 2025 report, where revenue was US$384.5 million and basic EPS came in at US$0.30, with net income excluding extra items of US$49.3 million. Over recent quarters, the company has reported revenue of US$429.99 million in Q4 2024, US$390.7 million in Q2 2025, and US$394.2 million in Q3 2025. Quarterly basic EPS over that period was US$0.90 in Q4 2024, US$0.50 in Q3 2025, and US$0.30 in Q4 2025. These...

Tango Therapeutics recently outlined leadership changes, including appointing Malte Peters as CEO and moving Barbara Weber to Executive Chair, alongside plans for pivotal trials and a pan-RAS supply agreement, while also granting equity awards to its new CFO and another employee under its 2023 Inducement Plan. These developments highlight how Tango’s evolving leadership structure and long-term incentive grants are being aligned with upcoming clinical milestones and partnership...

In late April and early May 2026, Gen Digital’s Norton brand rolled out major upgrades to its AI-native Norton Neo browser and related AI security tools, embedding built-in VPN, anti-phishing, anti-fingerprinting, and AI agent protections, while also expanding partnerships with xAI and Microsoft for secure AI and financial experiences. These launches, combined with new AI agent-focused VPN offerings and fresh third‑party awards for Norton, Avast, AVG, and Avira, highlight Gen’s push to...

Seadrill stock snapshot after recent performance Seadrill (SDRL) has drawn fresh attention after recent trading, with the stock last closing at US$48.90 and showing mixed short term returns, including a 0.9% decline over the past day and 1.8% decline over the past week. See our latest analysis for Seadrill. While Seadrill’s 1 day and 7 day share price returns are slightly negative, the 30 day and 90 day share price returns of 7.2% and 23.5%, together with a 1 year total shareholder return of...

Revvity Q1 2026 earnings snapshot Revvity (RVTY) has just put fresh numbers on the table, with recent quarters showing revenue between US$664.8 million and US$772.1 million and basic EPS ranging from US$0.35 to US$0.85 as the company heads into its Q1 2026 update. Over the past year, revenue has been recorded from US$684.0 million in Q3 2024 up to US$772.1 million in Q4 2025, while basic EPS prints in that stretch run from US$0.35 to US$0.85, giving investors a clear view of how the top line...

Clinical partnership puts Vir Biotechnology in focus Vir Biotechnology (VIR) has drawn fresh attention after finalizing its collaboration with Astellas Pharma on VIR-5500 for prostate cancer and treating the first patient in an expansion cohort of its Phase 1 metastatic prostate cancer trial. See our latest analysis for Vir Biotechnology. The recent collaboration news comes against a backdrop of strong momentum, with a 30 day share price return of 10.49% and a year to date share price return...

Two Harbors Investment (NYSE:TWO) is the subject of a takeover battle involving competing bids from UWM Holdings and CrossCountry Mortgage. The board of NYSE:TWO has rejected multiple acquisition attempts from UWM Holdings and is backing a fully financed, all-cash offer from CrossCountry Mortgage. The contest now centers on a shareholder vote, proxy solicitations, and competing arguments about value, deal structure, and execution risk. For you as a NYSE:TWO shareholder, this is not a...

Wondering if Ally Financial at around US$43 per share still offers value, or if most of the easy gains are behind it, starts with understanding what the current price is actually reflecting. The stock has had mixed recent returns, with a 2.7% decline over the last week, an 8.5% gain over the last month, a 5.6% decline year to date, and a 36.8% return over the last year alongside an 88.9% three year return and a 2.9% five year decline. Recent coverage has focused on how Ally Financial fits...

Avista’s Q1 2026 earnings in focus Avista (AVA) has rolled into Q1 2026 on the back of a solid run through 2025, capped by Q4 revenue of US$533 million and basic EPS of US$0.87, alongside trailing 12 month EPS of US$2.38 on US$1.96 billion of revenue. Over recent quarters, the company has seen revenue hold in a US$394 million to US$617 million range while quarterly EPS moved between US$0.17 and US$0.98. The trailing net profit margin is 9.8% compared with 9.3% a year earlier, which puts the...

In the past quarter, Adaptive Biotechnologies reported first‑quarter 2026 revenue of US$70.87 million, up from US$52.44 million a year earlier, while narrowing its net loss to US$20.03 million and reducing basic loss per share from US$0.20 to US$0.13. The results were powered by Minimal Residual Disease testing, with clonoSEQ volumes rising strongly and management raising full‑year 2026 MRD revenue guidance to US$260–US$270 million, underscoring the segment’s growing importance to the...

AGCO (AGCO) has just opened Q1 2026 earnings season with recent quarterly numbers that plot a sharp swing in profitability, moving from a Q4 2024 net loss of US$255.7 million on US$2,887.3 million of revenue and EPS of US$3.43 loss, to Q4 2025 net income of US$95.5 million on US$2,920.2 million of revenue and EPS of US$1.29. Over the same period, trailing twelve month EPS shifted from a US$5.69 loss on US$11.7 billion of revenue to US$9.76 on US$10.1 billion. Revenue moved from US$2,599.3...

In late April 2026, Opera Limited reported past first-quarter 2026 results showing sales of US$175.77 million and net income of US$24.79 million, alongside higher basic and diluted EPS of US$0.27 from continuing operations. On the same day, Opera raised its full-year 2026 revenue outlook to US$727 million–US$740 million and projected robust double-digit year-over-year growth for both the second quarter and the full year, highlighting management’s confidence in the business. With Opera...

Investors may be wondering if ConocoPhillips at around US$123.32 still offers value after a strong run, or if recent enthusiasm has already been priced in. The stock has seen a 27.5% return year to date and 45.5% over the last year, even though the last 7 days and 30 days showed returns of a 0.8% decline and a 5.5% decline, respectively. Recent coverage has focused on ConocoPhillips as a major integrated energy producer, with attention on how it is positioning its portfolio and capital...

Pinnacle Financial Partners, Inc. has already reported first‑quarter 2026 results, with net income rising to US$150 million from US$140 million a year earlier, while basic and diluted earnings per share from continuing operations fell to US$0.89 from about US$1.78 and US$1.77, respectively. This combination of higher total profit but sharply lower per‑share earnings, alongside AI-driven trading showing mixed time‑horizon sentiment, adds complexity to how investors may interpret Pinnacle’s...

AnaptysBio recently reported that the Delaware Chancery Court dismissed Tesaro’s anticipatory breach of contract claim over their Jemperli collaboration, while CEO Daniel Faga is set to discuss the company’s royalty assets at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference on May 6, 2026. This legal outcome, combined with a stronger earnings outlook highlighted by an upgraded Zacks rank, strengthens AnaptysBio’s position around its Jemperli-related royalty rights. We’ll now...